Brisbane, Australia, 11th-13th September 2020: DermaSensor, the medical device company that enables healthcare professionals to efficiently check for skin cancer, will demonstrate its revolutionary skin cancer detection technology at the General Practice Conference & Exhibition in Brisbane.
The General Practice Conference & Exhibition (GPCE) in Brisbane is Queensland’s leading CPD event for primary care and is one of the most important CPD events on the general practice calendar. Hundreds of healthcare professionals will meet to update knowledge, earn CPD points and see the latest primary care innovations.
The GPCE arms attendees with the cross-disciplinary skills that make a real difference to everyday practice across the full spectrum of primary care. The event delivers the latest relevant, practical, and implementable clinical updates, allows practitioners to earn CPD points/hours, connect with peers from around the nation, and discover the latest medical innovations from a vast network of local suppliers.
Kevin Scrimshaw, Commercial Director, ANZ and Martina Clark Territory Business Manager, VIC Australia from the DermaSensor team will show the audience the DermaSensor device, a revolutionary, world-first technology, designed to augment clinician decision making by providing accurate differentiation between malignant and benign skin lesions.
“We look forward to the opportunity to present DermaSensor’s technology and show how it can help clinicians quickly and effectively check for skin cancer,” explains Kevin. “The device can assess a lesion in under 30 seconds using optical spectroscopy and machine learning technology, and will one day, hopefully become a standard tool of the trade in primary care,” he says.
This exciting breakthrough was achieved using Elastic Scattering Spectroscopy – a technology pioneered at Boston University and University College London that uses light to evaluate cellular and subcellular structures of the skin.
DermaSensor has spent the past three years miniaturising its spectroscopy technology into an easy-to-use, handheld device. A physician gently touches the non-invasive device tip to a selected mole and a spectral sensor records how dozens of wavelengths of light reflect off cells beneath the surface of the skin. The company’s proprietary algorithm instantly analyses the reflected photons to provide a simple “Higher Risk” or “Lower Risk” output that supports a physician’s referral decision, converging the powers of machine learning and clinical evaluation.
The device is undergoing FDA and TGA approval and is expected to be available in Australia in late-2020. This low-cost, easy-to-use device enables healthcare providers and patients to access fast, accurate skin lesion assessments to ultimately improve outcomes for patients with skin cancer.
Its speed and ease of use improves workflow by extending lesion identification and evaluation to trained team members. Patients can expect to experience fewer unnecessary complications or side effects and medical practitioners may spend less time on lengthy procedures.